1. Selinexor population pharmacokinetic and exposure–response analyses to support dose optimization in patients with diffuse large B-cell lymphoma
- Author
-
Hanbin Li, Russ Wada, Justin C Bader, Sharon Shacham, Shijie Tang, Jatin P. Shah, and Hongmei Xu
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Population ,Cmax ,Toxicology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Adverse effect ,education ,Aged ,Aged, 80 and over ,Pharmacology ,Volume of distribution ,education.field_of_study ,business.industry ,Lymphoma, Non-Hodgkin ,Clinical Studies as Topic ,Middle Aged ,Triazoles ,medicine.disease ,Lymphoma ,Regimen ,Hydrazines ,Treatment Outcome ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,Lymphoma, Large B-Cell, Diffuse ,business ,Diffuse large B-cell lymphoma - Abstract
Characterize the population PK and exposure–response (ER) relationships of selinexor in patients with diffuse large B-cell lymphoma (DLBCL) (efficacy endpoints) or other non-Hodgkin’s lymphoma (NHL) patients (safety endpoints) to determine the optimal dose in patients with DLBCL. This work included patients from seven clinical studies, with 800 patients for PK, 175 patients for efficacy and 322 patients for safety analyses. Logistic regression models and Cox-regression models were used for binary and time-to-event endpoints, respectively. Model-based simulations were performed to justify dose based on balance between efficacy and safety outcome. Selinexor pharmacokinetics were well-described by a two-compartment model with body weight as a significant covariate on clearance and central volume of distribution and gender on clearance. Overall response rate (ORR) in patients with DLBCL increased with day 1 Cmax and decreased in patients with higher baseline tumor size (p
- Published
- 2021